Lavrov V N, Shchapov A Iu, Berentsveĭg B R
Med Tekh. 1994 Mar-Apr(2):12-4.
The paper deals with the experimental and clinical study of a new implantable therapeutical means based on biocompatible implants containing the antituberculous agent benemycin. The developed implantant having 4 coatings releases within 10 days as high as 37% of the applied drug benemycin. Then within further 30-70 days, release of the drug is 0.7% a day. The parallel bacteriological studies with the operative material placed in agar made 30-60 days after surgery have indicated that growth retardment in rabbits is 17-30 mm, which corresponds to the levels of rifandin (0.125-1.0 microgram/g tissue. The developed implantant has been used in 130 cases of the surgical treatment of tuberculous spondylitis in order to replace a defect of the body of a vertebra and to make a depot for the antituberculous drug just in the focus. Formation of the pulley at the site of intervention was noted in 57 (43.8%) cases within 5 months and in 62 (47.7%) cases within 10 months. The developed implantant has no toxicity and produces no allergic reactions. The position results of the treatment allows it to be recommended for use in clinical practice.
本文论述了一种基于含有抗结核药物贝那霉素的生物相容性植入物的新型可植入治疗手段的实验和临床研究。所研发的具有4层涂层的植入物在10天内释放出高达37%的所施用药物贝那霉素。然后在接下来的30 - 70天内，药物释放量为每天0.7%。对术后30 - 60天置于琼脂中的手术材料进行的平行细菌学研究表明，家兔体内的生长抑制为17 - 30毫米，这与利凡丁的水平相当（0.125 - 1.0微克/克组织）。所研发的植入物已用于130例结核性脊柱炎的手术治疗，以替代椎体缺损并在病灶处形成抗结核药物储存库。57例（43.8%）在5个月内、62例（47.7%）在10个月内在干预部位出现滑轮形成。所研发的植入物无毒且不产生过敏反应。治疗的定位结果使其可推荐用于临床实践。
